102 related articles for article (PubMed ID: 30561126)
1. Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database.
Okada N; Niimura T; Zamami Y; Hamano H; Ishida S; Goda M; Takechi K; Chuma M; Imanishi M; Ishizawa K
Cancer Med; 2019 Jan; 8(1):174-181. PubMed ID: 30561126
[TBL] [Abstract][Full Text] [Related]
2. Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System.
Suzuki S; Imai S; Mitsuboshi S; Kizaki H; Hashiguchi M; Hori S
J Clin Pharmacol; 2023 Aug; 63(8):903-908. PubMed ID: 37042319
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases.
Neishi M; Hamano H; Niimura T; Denda M; Yagi K; Miyata K; Lin TJ; Higashionna T; Goda M; Zamami Y; Ishizawa K; Nawa H
Toxicol Appl Pharmacol; 2023 Sep; 475():116632. PubMed ID: 37482254
[TBL] [Abstract][Full Text] [Related]
4. Disproportionality analysis of stomatitis associated with anticancer drugs using Japanese Adverse Drug Event Reporting Database.
Hosonaka K; Yamaoka K; Ikeda N; Uchida M; Uesawa Y; Takahashi K; Shimizu T
Oncology; 2024 Jan; ():. PubMed ID: 38198784
[TBL] [Abstract][Full Text] [Related]
5. Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance.
Li W; Wang W
Invest New Drugs; 2024 Jun; 42(3):335-339. PubMed ID: 38700578
[TBL] [Abstract][Full Text] [Related]
6. Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes.
Fisher JL; Clark AD; Jones EF; Lasseigne BN
BMC Pharmacol Toxicol; 2024 Jan; 25(1):5. PubMed ID: 38167211
[TBL] [Abstract][Full Text] [Related]
7. Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes.
Fisher JL; Clark AD; Jones EF; Lasseigne BN
bioRxiv; 2023 Nov; ():. PubMed ID: 37362157
[TBL] [Abstract][Full Text] [Related]
8. Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS.
Schilder JM; Golembesky A; Boyle TAC; Ye GL; Kuplast J
Front Pharmacol; 2023; 14():1241524. PubMed ID: 37663271
[No Abstract] [Full Text] [Related]
9. BCR-ABL testing in the evaluation of neutrophilia.
Smith CJ; Ruan GJ; Kluck LA; Maberry M; Go RS
Am J Hematol; 2024 May; ():. PubMed ID: 38760992
[No Abstract] [Full Text] [Related]
10. Evaluating adverse events in databases.
Lovell K; Feldman SR
Pharmacol Res Perspect; 2023 Oct; 11(5):e01129. PubMed ID: 37589317
[No Abstract] [Full Text] [Related]
11. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases.
Mukai R; Hasegawa S; Umetsu R; Nakao S; Shimada K; Uranishi H; Masuta M; Suzuki H; Nishibata Y; Nakamura M
J Clin Pharm Ther; 2019 Apr; 44(2):285-291. PubMed ID: 30569470
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory bowel disease associated with the combination treatment of nivolumab and metformin: data from the FDA adverse event reporting system.
Zhou H; Liu J; Zhang Y; Zhang L
Cancer Chemother Pharmacol; 2019 Mar; 83(3):599-601. PubMed ID: 30623231
[TBL] [Abstract][Full Text] [Related]
13. Large-scale mining disease comorbidity relationships from post-market drug adverse events surveillance data.
Zheng C; Xu R
BMC Bioinformatics; 2018 Dec; 19(Suppl 17):500. PubMed ID: 30591027
[TBL] [Abstract][Full Text] [Related]
14. Adverse event reporting patterns of concomitant botanical dietary supplements with CYP3A4 interactive & CYP3A4 non-interactive anticancer drugs in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Fahim SM; Mishuk AU; Cheng N; Hansen R; Calderón AI; Qian J
Expert Opin Drug Saf; 2019 Feb; 18(2):145-152. PubMed ID: 30576263
[TBL] [Abstract][Full Text] [Related]
15. Analysis of patients with drug-induced pemphigoid using the Japanese Adverse Drug Event Report database.
Tanaka H; Ishii T
J Dermatol; 2019 Mar; 46(3):240-244. PubMed ID: 30575097
[TBL] [Abstract][Full Text] [Related]
16. Rhabdomyolysis risk from the use of two-drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis.
Gosho M
Fundam Clin Pharmacol; 2019 Jun; 33(3):339-346. PubMed ID: 30575126
[TBL] [Abstract][Full Text] [Related]
17. Analysis of fall-related adverse events among older adults using the Japanese Adverse Drug Event Report (JADER) database.
Hatahira H; Hasegawa S; Sasaoka S; Kato Y; Abe J; Motooka Y; Fukuda A; Naganuma M; Nakao S; Mukai R; Shimada K; Hirade K; Kato T; Nakamura M
J Pharm Health Care Sci; 2018; 4():32. PubMed ID: 30574336
[TBL] [Abstract][Full Text] [Related]
18. Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect.
Yagi K; Mitstui M; Zamami Y; Niimura T; Izawa-Ishizawa Y; Goda M; Chuma M; Fukunaga K; Shibata T; Ishida S; Sakurada T; Okada N; Hamano H; Horinouchi Y; Ikeda Y; Yanagawa H; Ishizawa K
Cancer Med; 2021 Jan; 10(1):164-172. PubMed ID: 33231381
[TBL] [Abstract][Full Text] [Related]
19. The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis.
Asada M; Mikami T; Niimura T; Zamami Y; Uesawa Y; Chuma M; Ishizawa K
Oncology; 2021; 99(4):256-259. PubMed ID: 33477139
[TBL] [Abstract][Full Text] [Related]
20. Successful Vancomycin Dose Adjustment in a Sepsis patient with Bacterial Meningitis Using Cystatin C.
Chuma M; Kondo M; Zamami Y; Takechi K; Goda M; Okada N; Shibata A; Asada M; Oto J; Yanagawa H; Ishizawa K
Acta Med Okayama; 2020 Aug; 74(4):365-370. PubMed ID: 32843769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
